Shares of BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) saw unusually-strong trading volume on Tuesday . 455,204 shares were traded during trading, an increase of 6% from the previous session’s volume of 430,168 shares.The stock last traded at $2.57 and had previously closed at $2.71.

Separately, Maxim Group reaffirmed a “buy” rating and set a $5.00 target price on shares of BrainStorm Cell Therapeutics in a report on Monday.

The company’s 50 day moving average price is $2.49 and its 200 day moving average price is $2.42. The firm’s market capitalization is $48.31 million.

BrainStorm Cell Therapeutics (NASDAQ:BCLI) last posted its earnings results on Tuesday, May 10th. The biotechnology company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.15. Equities analysts predict that BrainStorm Cell Therapeutics Inc. will post ($0.58) EPS for the current year.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.